Investor Relations

Quidel - Our Story

Quidel is Well-Positioned in Point-of-Care Diagnostic Testing Market

Strong secular trends support increased diagnostics utilization. Healthcare is moving closer to the patient: Urgent Care, Free-Standing Emergency Departments, Pharmacies, Retail Clinics. Health care providers are focused on reducing costs, demonstrating value, and creating positive patient outcomes.

Innovative Point-of-Care Sofia® Technology Enables a Physician to Test and Treat in One Office Visit

Easy to Use Sofia® analyzers provide diagnostic answers between 3 and 15 minutes. Assays deliver an accurate, cost effective, and reliable result without the need for extensive technician training.

Innovative Product Pipeline

Quidel’s R&D engine has received over 30 FDA clearances for multiple conditions and infectious diseases since 2011. Savanna® MDx platform that is currently under development will compete in the high-growth molecular diagnostics segment. Incremental Triage® product introductions are intended to drive growth.

Strong Management Team Focused on Delivering Consistent Execution

Quidel’s non-Triage® business grew at an 11% CAGR from 2010 – 2018. Recent Triage® acquisition and integration has created a global commercial and distribution presence.

High Gross Margin Products with Efforts Focused on Longer-term Margin Expansion Opportunities

Gross margin of 60% in fiscal 2018; management focused on longer-term goal of 65% gross margin. Generated in excess of $100 million in Operating Cash Flow in fiscal 2018 with a long term objective toward $200 million.

Disciplined Capital Allocation Strategy

Focus on continued investment in R&D, adding more assays to Sofia platform, as well as strengthening our molecular diagnostics presence. Aggressive debt reduction over the last two years (from 4X leverage in October 2017 to under 1X at the end of 2018), and could support future M&A opportunities.

Cautionary Information

Corporate Profile

Quidel Corporation (Nasdaq: QDEL) is a California-based leading manufacturer of diagnostic healthcare solutions serving to enhance the health and well-being of people around the globe through the development of diagnostic solutions that accurately and quickly diagnose infectious diseases, as well as cardiovascular and metabolic conditions, allowing healthcare workers to quickly test and treat at the point-of-care, which leads to improved patient outcomes, providing numerous economic benefits to the healthcare system.

Read More

Recent News

View All News

Recent Events

View All Events

INVESTOR PRESENTATION

Quarterly Results

View All Quarters

Archived financial results

Analyst Coverage

Firm Analyst Phone
Barclays Capital Jack Meehan 212-526-3909
Canaccord Genuity Mark Massaro 617-371-3769
Craig-Hallum Capital Group, LLC Alex Nowak 612-334-6347
J.P. Morgan Tycho Peterson 212-622-6568
Piper Jaffray William R. Quirk 612-303-6858
Raymond James John Hsu 617-897-8993
William Blair Brian Weinstein 312-364-8170

As of September 9, 2019, Quidel Corporation is aware that it is followed by the analysts listed above; however, it is possible that the list above is not complete. Please note that any opinions, estimates or forecasts regarding Quidel Corporation's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Quidel Corporation or its management. Quidel Corporation does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

Interactive Analyst center

Income Statements (in millions, except per share amounts)

View more details